Immune profile of pediatric renal transplant recipients following alemtuzumab induction

Journal of the American Society of Nephrology

Volumn 23, Issue 1, 2012, Pages 174-182

  De Serres, Sacha A ^a   Mfarrej, Bechara G ^a   Magee, Ciara N ^a   Benitez, Fanny ^a   Ashoor, Isa ^a   Sayegh, Mohamed H ^a   Harmon, William E ^b   Najafian, Nader ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CALCINEURIN INHIBITOR; HLA ANTIBODY; TRANSCRIPTION FACTOR FOXP3; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADOLESCENT; ARTICLE; CATHETER INFECTION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CYSTITIS; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; INFECTION PREVENTION; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAINTENANCE THERAPY; MALE; MEMORY CELL; PNEUMONIA; PRIORITY JOURNAL; PYELONEPHRITIS; REGULATORY T LYMPHOCYTE; RENAL GRAFT DYSFUNCTION; SCHOOL CHILD; SINUSITIS; SKIN INFECTION; T CELL DEPLETION; TREATMENT WITHDRAWAL; VIREMIA;

EID: 84855608212     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2011040360     Document Type: Article

References (28)

1. Pearl JP, Parris J, Hale DA, Hoffmann SC, Bernstein WB, McCoy KL, Swanson SJ, Mannon RB, Roederer M, Kirk AD: Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 5: 465-474, 2005 (Pubitemid 40313337)
2. Trzonkowski P, Zilvetti M, Chapman S, Wieckiewicz J, Sutherland A, Friend P, Wood KJ: Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant 8: 338-347, 2008
3. Ciancio G, Burke GW 3rd: Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 8: 15-20, 2008
4. 1H). Clin J Am Soc Nephrol 1: 539-545, 2006
5. Noris M, Casiraghi F, Todeschini M, Cravedi P, Cugini D, Monteferrante G, Aiello S, Cassis L, Gotti E, Gaspari F, Cattaneo D, Perico N, Remuzzi G: Regulatory T cells and T cell depletion: Role of immunosuppressive drugs. J Am Soc Nephrol 18: 1007-1018, 2007 (Pubitemid 46434518)
6. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N: A novel mechanism of action for anti-thymocyte globulin: Induction of CD4+ CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 17: 2844-2853, 2006 (Pubitemid 44484674)
7. Knechtle SJ, Pirsch JD, Fechner JH Jr, Becker BN, Friedl A, Colvin RB, Lebeck LK, Chin LT, Becker YT, Odorico JS, D'Alessandro AM, Kalayoglu M, Hamawy MM, Hu H, Bloom DD, Sollinger HW: Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 3: 722-730, 2003 (Pubitemid 36745245)
8. Flechner SM, Friend PJ, Brockmann J, Ismail HR, Zilvetti M, Goldfarb D, Modlin C, Mastroianni B, Savas K, Devaney A, Simmonds M, Cook DJ: Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 5: 3009-3014, 2005 (Pubitemid 43923964)
9. Knechtle SJ, Pascual J, Bloom DD, Torrealba JR, Jankowska-Gan E, Burlingham WJ, Kwun J, Colvin RB, Seyfert-Margolis V, Bourcier K, Sollinger HW: Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: Clinical results and immune monitoring. Am J Transplant 9: 1087-1098, 2009
10. Pascual J, Pirsch JD, Odorico JS, Torrealba JR, Djamali A, Becker YT, Voss B, Leverson GE, Knechtle SJ, Sollinger HW, Samaniego-Picota MD: Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. Transplantation 87: 125-132, 2009
11. Moudgil A, Puliyanda D: Induction therapy in pediatric renal transplant recipients: An overview. Paediatr Drugs 9: 323-341, 2007 (Pubitemid 47557114)
12. 1H use in pediatric renal transplantation. Am J Transplant 5: 1569-1573, 2005
13. Tan HP, Donaldson J, Ellis D, Moritz ML, Basu A, Morgan C, Vats AN, Erkan E, Shapiro R: Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience. Transplantation 86: 1725-1731, 2008
14. 1H (C1H) in intestinal and liver transplantation. Transplantation 75: 1227-1231, 2003
15. Mueller TF: Phenotypic changes with immunosuppression in human recipients. Front Biosci 8: d1254-d1274, 2003
16. Bloom DD, Chang Z, Fechner JH, Dar W, Polster SP, Pascual J, Turka LA, Knechtle SJ: CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 8: 793-802, 2008 (Pubitemid 351347746)
17. 1H in organ transplantation and its potential use in pediatric recipients. Pediatr Transplant 8: 106-112, 2004
18. Mackall CL, Gress RE: Thymic aging and T-cell regeneration. Immunol Rev 160: 91-102, 1997 (Pubitemid 28021369)
19. Scarsi M, Bossini N, Malacarne F, Valerio F, Sandrini S, Airò P: The number of circulating recent thymic emigrants is severely reduced 1 year after a single dose of alemtuzumab in renal transplant recipients. Transpl Int 23: 786-795, 2010
20. 1H in BMT patients. Cytotherapy 3: 261-267, 2001
21. Pearl JP, Preston E, Kirk AD: Tolerance: Is it achievable in pediatric solid organ transplantation? Pediatr Clin North Am50: 1261-1281, vii, 2003
22. De Serres SA, Sayegh MH, Najafian N: Immunosuppressive drugs and Tregs: A critical evaluation! Clin J Am Soc Nephrol 4: 1661-1669, 2009
23. Neujahr DC, Chen C, Huang X, Markmann JF, Cobbold S, Waldmann H, Sayegh MH, Hancock WW, Turka LA: Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J Immunol 176: 4632-4639, 2006
24. Lanzavecchia A, Sallusto F: Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 17: 326-332, 2005 (Pubitemid 40692670)
25. Terasaki PI, Ozawa M: Predicting kidney graft failure by HLA antibodies: A prospective trial. Am J Transplant 4: 438-443, 2004 (Pubitemid 38282302)
26. Hourmant M, Cesbron-Gautier A, Terasaki PI, Mizutani K, Moreau A, Meurette A, Dantal J, Giral M, Blancho G, Cantarovich D, Karam G, Follea G, Soulillou JP, Bignon JD: Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 16: 2804-2812, 2005
27. De Serres SA, Mfarrej BG, Guleria I, Najafian N, Morrison Y, Bridges N, Ikle D, Vincenti F, Harmon WH, Sayegh MH, Chandraker A: Silent development of de novo anti-HLA antibodies following transplantation is associated with histological changes in the allograft. Interim report on behalf of the CTOT-02/CCTPT-02 study [abstract SA-FC446]. J Am Soc Nephrol 21: 102A, 2010
28. Najafian N, Salama AD, Fedoseyeva EV, Benichou G, Sayegh MH: Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: Potential novel assay for prediction of outcomes for renal transplant recipients. J Am Soc Nephrol 13: 252-259, 2002 (Pubitemid 34042035)